Your session is about to expire
← Back to Search
Other
Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC
Phase 1
Waitlist Available
Research Sponsored by Dizal Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through the study completion, an average of around 1 year
Awards & highlights
No Placebo-Only Group
Summary
This trial will test a new drug called DZD2269 in patients with advanced prostate cancer that has not responded to other treatments. The study aims to find out if the drug is safe, how it behaves in the body, and if it can help fight the cancer. This is the first time DZD2269 is being tested in humans.
Eligible Conditions
- Prostate Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through the study completion, an average of around 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through the study completion, an average of around 1 year
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Incidence of AEs and SAEs
Incidence of DLTs
Secondary study objectives
Area under the plasma concentration-time curve (AUC) of DZD2269
Disease Control Rate (DCR);
Drug concentrations of DZD2269 in plasma and urine
+3 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: DZD2269 as monotherapyExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
DZD2269
2021
Completed Phase 1
~80
Find a Location
Who is running the clinical trial?
Dizal PharmaceuticalsLead Sponsor
24 Previous Clinical Trials
2,858 Total Patients Enrolled